Nanomedicine Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Posted on June 16, 2020 by Prof Baldwin

New Jersey, United States,- A detailed research study on Nanomedicine Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Nanomedicine, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=201321&utm_source=COD&utm_medium=888

Leading Nanomedicine manufacturers/companies operating at both regional and global levels:

Nanomedicine Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Nanomedicine market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nanomedicine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Nanomedicine Market, By Product

Nanomedicine Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201321&utm_source=COD&utm_medium=888

Nanomedicine Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Nanomedicine market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Nanomedicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanomedicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanomedicine Market, By Deployment Model

5.1 Overview

6 Nanomedicine Market, By Solution

6.1 Overview

7 Nanomedicine Market, By Vertical

7.1 Overview

8 Nanomedicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanomedicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=201321&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Display Driver Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Floating Production Storage Offloading (Fpso) Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Mice Model Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Nanomedicine Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept – BioSpace

Posted on May 8, 2020 by Prof Baldwin

TORONTO, May 5, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) -Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a subsidiary company, Saugatuck Therapeutics Ltd. ("Saugatuck"). Portage Biotech Inc. holds an 70% equity interest in Saugatuck.

Portage is pleased to announce that initial proof of concept of the nanolipogel ("NLG") formulation has been achieved with the initial investment. This has triggered the next tranche of capital infusion of $700,000 USD. Saugatuck has been able to formulate a proprietary PD1 aptamer in the NLG formulation and have shown the formulation properly modulates PD1 signaling. In non clinical in vivo experiments, the NLG-PD1 performed favorably compared to a mouse PD1 antibody. The additional founding will support exploration of multiple PD1 based co-formulations with small molecules and other DNA aptamers.

Separately, this work has triggered a license from D5 pharma to create additional proprietary DNA aptamers for immune-oncology targets. This license sits in another Portage company, Oncomer. Oncomer supplies Saugatuck with aptamers to be formulated in the NLG platform.

Dr. Ian Walters, CEO of Saugatuck and Portage commented, "Most cancers are treated with multiple agents. Our co-formulation platform leverages the ability to modulate several pathways in a single product and direct its distribution to tumors. I am excited to begin testing our next wave of combinations in animal models and prioritizing our first clinical candidate."

About Saugatuck Therapeutics Ltd.

NLG technology, invented in the lab of Dr. Tarek Fahmy at Yale University and commercially developed by our joint venture partner, Immunova,allows different combinations of drugs to be encapsulated in a single nanomedicine and delivered selectively to the tumor microenvironment, thus potentially minimizing systemic side-effects. Saugatuck which has acquired an exclusive license from Yale University via Immunova for use of the NLG platform for delivering DNA aptamers and certain aptamer-based combination products. Immunova is developing a pipeline of NLG drugs focused on cytokine and other immune modulating drugs.

About Portage Biotech Inc.

Portage is a unique entity in the world of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services, to enable efficient, turnkey execution of commercially-informed development plans. Our portfolio encompasses nine subsidiary companies whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development strategies, to cost-effectively deliver best-in-class R&D, clinical trial design, and financial and project management, to ultimately build value and support commercial potential.

About D5pharma:

D5Pharma is an early stage biotech based out of Sunnybrook Research Institute in Toronto that identifies novel DNA scaffold molecules for therapeutic development in oncology and inflammatory diseases. Its most advanced compound in development is an anti-CD200R1 aptamer for the treatment of asthma that was developed out of the laboratory of Dr. Jean Gariepy. This new partnership with Oncomer will enable D5 to build out its oncology portfolio by delivering aptamers in new and more effective ways.

Forward-Looking Statements

This news release contains statements about the Company's information that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

View original content:http://www.prnewswire.com/news-releases/portage-makes-an-additional-investment-in-saugatuck-therapeutics-after-achieving-proof-of-concept-301052356.html

SOURCE Portage Biotech Inc.

Impact of COVID-19 on Nanomedicine Market Top Companies Analysis To growing at CAGR of 12.6% by 2023 – Cole of Duty

Posted on June 11, 2020 by Prof Baldwin

UPDATE AVAILABLE ON-DEMAND

Global Nanomedicine Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report.

The global nanomedicine market was valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2021

Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.

The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.

The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2021

The Major Key Players Are:

The Other Prominent Players Are:

Similar Reports:

Healthcare Payer Solution Market Global Opportunity Analysis and Industry Forecast, 2020-2027

Pharmerging Market Global Opportunity Analysis and Industry Forecast, 2020-2027

HIV Diagnosis Market Global Opportunity Analysis and Industry Forecast, 2020-2027

Hybrid Imaging Market Global Opportunity Analysis and Industry Forecast, 2020-2027

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Contact:

David CorreaPortland, OR, United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975[emailprotected]Web:https://www.alliedmarketresearch.comFollow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

See original here:
Impact of COVID-19 on Nanomedicine Market Top Companies Analysis To growing at CAGR of 12.6% by 2023 - Cole of Duty

International Journal of Nanomedicine | Volume 13 – Dove Press

Posted on January 6, 2019 by Prof Baldwin

Silicagentamicin nanohybrids: combating antibiotic resistance, bacterial biofilms, and in vivo toxicity

Mosselhy DA, He W, Hynnen U, Meng Y, Mohammadi P, Palva A, Feng QL, Hannula SP, Nordstrm K, Linder MB

International Journal of Nanomedicine 2018, 13:8577-8578

Published Date: 13 December 2018

Strojny B, Sawosz E, Grodzik M, Jaworski S, Szczepaniak J, Sosnowska M, Wierzbicki M, Kutwin M, Orliska S, Chwalibog A

International Journal of Nanomedicine 2018, 13:8561-8575

Published Date: 13 December 2018

Belle Ebanda Kedi P, Eya'ane Meva F, Kotsedi L, Nguemfo EL, Bogning Zangueu C, Ntoumba AA, Mohamed HEA, Dongmo AB, Maaza M

International Journal of Nanomedicine 2018, 13:8537-8548

Published Date: 12 December 2018

Wu M, Liu J, Hu C, Li D, Yang J, Wu Z, Yang L, Chen Y, Fu S, Wu J

International Journal of Nanomedicine 2018, 13:8461-8472

Published Date: 11 December 2018

Perera PGT, Nguyen THP, Dekiwadia C, Wandiyanto JV, Sbarski I, Bazaka O, Bazaka K, Crawford RJ, Croft RJ, Ivanova EP

International Journal of Nanomedicine 2018, 13:8429-8442

Published Date: 10 December 2018

Shen Y, Yu Y, Chaurasiya B, Li X, Xu Y, Webster TJ, Tu J, Sun R

International Journal of Nanomedicine 2018, 13:8281-8296

Published Date: 5 December 2018

Yan J, Zhang H, Cheng F, He Y, Su T, Zhang X, Zhang M, Zhu Y, Li C, Cao J, He B

International Journal of Nanomedicine 2018, 13:8247-8268

Published Date: 4 December 2018

Renu S, Markazi AD, Dhakal S, Lakshmanappa YS, Gourapura SR, Shanmugasundaram R, Senapati S, Narasimhan B, Selvaraj RK, Renukaradhya GJ

International Journal of Nanomedicine 2018, 13:8195-8215

Published Date: 30 November 2018

Mosselhy DA, He W, Hynnen U, Meng Y, Mohammadi P, Palva A, Feng QL, Hannula SP, Nordstrm K, Linder MB

International Journal of Nanomedicine 2018, 13:7939-7957

Published Date: 28 November 2018

Wang Y, Chen H, Zhang X, Gui L, Wu J, Feng Q, Peng S, Zhao M

International Journal of Nanomedicine 2018, 13:7835-7844

Published Date: 22 November 2018

Lu MM, Ge YR, Qiu J, Shao D, Zhang Y, Bai J, Zheng X, Chang ZM, Wang Z, Dong WF, Tang CB

International Journal of Nanomedicine 2018, 13:7697-7709

Published Date: 19 November 2018

Yuan Z, Yuan Y, Han L, Qiu Y, Huang X, Gao F, Fan G, Zhang Y, Tang X, He X, Xu K, Yin P

International Journal of Nanomedicine 2018, 13:7533-7548

Published Date: 15 November 2018

Wang B, Guo Y, Chen X, Zeng C, Hu Q, Yin W, Li W, Xie H, Zhang B, Huang X, Yu F

International Journal of Nanomedicine 2018, 13:7395-7408

Published Date: 12 November 2018

Li D, Zhang K, Shi C, Liu L, Yan G, Liu C, Zhou Y, Hu Y, Sun H, Yang B

International Journal of Nanomedicine 2018, 13:7167-7181

Published Date: 6 November 2018

Kim DH, Kim JY, Kim RM, Maharjan P, Ji YG, Jang DJ, Min KA, Koo TS, Cho KH

International Journal of Nanomedicine 2018, 13:7095-7106

Published Date: 5 November 2018

Horvth T, Papp A, Igaz N, Kovcs D, Kozma G, Trenka V, Tiszlavicz L, Rzga Z, Knya Z, Kiricsi M, Vezr T

International Journal of Nanomedicine 2018, 13:7061-7077

Published Date: 2 November 2018

Lee D, Heo DN, Nah HR, Lee SJ, Ko WK, Lee JS, Moon HJ, Bang JB, Hwang YS, Reis RL, Kwon IK

International Journal of Nanomedicine 2018, 13:7019-7031

Published Date: 1 November 2018

Wang W, Nie W, Liu D, Du H, Zhou X, Chen L, Wang H, Mo X, Li L, He C

International Journal of Nanomedicine 2018, 13:7003-7018

Published Date: 1 November 2018

Lu Y, Jiang W, Wu X, Huang S, Huang Z, Shi Y, Dai Q, Chen J, Ren F, Gao S

International Journal of Nanomedicine 2018, 13:6913-6927

Published Date: 30 October 2018

Shi Ms, Zhao X, Zhang J, Pan S, Yang C, Wei Y, Hu H, Qiao M, Chen D, Zhao X

International Journal of Nanomedicine 2018, 13:6885-6902

Published Date: 26 October 2018

Nejadi Babadaei MM, Feli Moghaddam M, Solhvand S, Alizadehmollayaghoob E, Attar F, Rajabbeigi E, Akhtari K, Sari S, Falahati M

International Journal of Nanomedicine 2018, 13:6871-6884

Published Date: 26 October 2018

Vio V, Riveros AL, Tapia-Bustos A, Lespay-Rebolledo C, Perez-Lobos R, Muoz L, Pismante P, Morales P, Araya E, Hassan N, Herrera-Marschitz M, Kogan MJ

International Journal of Nanomedicine 2018, 13:6839-6854

Published Date: 25 October 2018

Qiu W, Chen R, Chen X, Zhang H, Song L, Cui W, Zhang J, Ye D, Zhang Y, Wang Z

International Journal of Nanomedicine 2018, 13:6809-6827

Published Date: 24 October 2018

Sun L, Xu J, Sun Z, Zheng F, Liu C, Wang C, Xiaoye Hu, Xia L, Liu Z, Xia R

International Journal of Nanomedicine 2018, 13:6769-6777

Published Date: 24 October 2018

Song Y, Ma A, Ning J, Zhong X, Zhang Q, Zhang X, Hong G, Li Y, Sasaki K, Li C

International Journal of Nanomedicine 2018, 13:6751-6767

Published Date: 23 October 2018

Dhakal S, Cheng X, Salcido J, Renu S, Bondra K, Lakshmanappa YS, Misch C, Ghimire S, Feliciano-Ruiz N, Hogshead B, Krakowka S, Carson K, McDonough J, Lee CW, Renukaradhya GJ

International Journal of Nanomedicine 2018, 13:6699-6715

Published Date: 24 October 2018

Rodallec A, Sicard G, Giacometti S, Carr M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R

International Journal of Nanomedicine 2018, 13:6677-6688

Published Date: 23 October 2018

Zhao X, Qi T, Kong C, Hao M, Wang Y, Li J, Liu B, Gao Y, Jiang J

International Journal of Nanomedicine 2018, 13:6413-6428

Published Date: 12 October 2018

Zhai B, Zeng Y, Zeng Z, Zhang N, Li C, Zeng Y, You Y, Wang S, Chen X, Sui X, Xie T

International Journal of Nanomedicine 2018, 13:6279-6296

Published Date: 10 October 2018

Zhou X, Shi G, Fan B, Cheng X, Zhang X, Wang X, Liu S, Hao Y, Wei Z, Wang L, Feng S

International Journal of Nanomedicine 2018, 13:6265-6277

Published Date: 10 October 2018

Hernandez-Delgadillo R, Garca-Cuellar CM, Snchez-Prez Y, Pineda-Aguilar N, Martnez-Martnez MA, Rangel-Padilla EE, Nakagoshi-Cepeda SE, Sols-Soto JM, Snchez-Njera RI, Nakagoshi-Cepeda MAA, Chellam, S, Cabral-Romero C

International Journal of Nanomedicine 2018, 13:6089-6097

Published Date: 5 October 2018

Kuroda C, Ueda K, Haniu H, Ishida H, Okano S, Takizawa T, Sobajima A, Kamanaka T, Yoshida K, Okamoto M, Tsukahara T, Matsuda Y, Aoki K, Kato H, Saito N

International Journal of Nanomedicine 2018, 13:6079-6088

Published Date: 5 October 2018

Yamoah MA, Moshref M, Sharma J, Chen WC, Ledford HA, Lee JH, Chavez KS, Wang W, Lpez JE, Lieu DK, Sirish P, Zhang XD

International Journal of Nanomedicine 2018, 13:6073-6078

Published Date: 5 October 2018

View post:
International Journal of Nanomedicine | Volume 13 - Dove Press

Global Nanorobotics Market : Industry Analysis and Forecast (2019-2026) by Type, Application, and Region – MR Invasion

Posted on May 7, 2020 by Prof Baldwin

Global Nanorobotics Market was valued at US$ 3.7 Bn in 2018 and is expected to reach US$ 9.2Bn by 2026, at a CAGR of 12.06%during a forecast period.

Developments in nanotechnology coupled with demand for minimally aggressive procedures are expected to drive market growth over the forecast period. Nanobots possess likely in the medical sector for destroying cancerous cells at the genetic level. Increasing support for nanomedicine by many nations and the increasing geriatric population are factors which can augur market demand.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/30888

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Utilization of nanobots in the ranostics can be beneficial for the market in the near future. A rise in miniaturization and demand for automation across various sectors are anticipated to fuel market growth. Training of new personnel to use nanobots can restrain market growth in the upcoming years.Nanomedicine application segment to grow at the highest CAGR during the forecast period. Nanorobotics is widely used in nanomedicine owning to its healthcare features. The large share of this application aspects to the large level of commercialization in the healthcare sector for drug delivery, in vivo imaging, biomaterial, in vitro diagnostic, active implants, and drug therapy.

North America region accounted for the largest share of 12.2%, in terms of value, of the nanorobotics market globally. Presence of many nanotechnology companies, well-developed healthcare infrastructure, and government initiatives to create patient awareness are factors driving the market. The U.S is anticipated to contribute to market revenue owing to the increase in cardiovascular diseases and the rising elderly populace.

Europe follows North America as the second biggest nanorobotics market. Presence of chronic diseases and the burgeoning population are factors expected to indicate the Europe nanobots market. Establishment of organizations to develop standards pertaining to nanotechnology can expand market growth. In 2018, DNA-Robotics, an organization including 12 European companies, has outlined steps to expedite production of nanobots on a large scale. These standards can help scale the market exponentially in the upcoming years.

A recent development in nanorobotics market: In March 2018, Thermo Fisher Scientific acquired Gatan, an exclusively owned subsidiary of Roper Technologies. Gatan is an electron microscopy solutions provider in the U.S, which accompaniments the Thermo Fisher Scientifics electron microscopy solutions business.In March 2017, Oxford Instruments (U.K) Asylum Research introduced its new SurfRider HQ-Series of high quality, budget-priced AFM probes, which are also existing in a model suitable for nanomechanical image mode.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Nanorobotics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTERs analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Nanorobotics Market.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/30888

Scope of the Global Nanorobotics Market

Global Nanorobotics Market, By Type

Nanomanipulatoro Electron Microscope (EM) Scanning Electron Microscope (SEM) Transmission Electron Microscope (TEM)o Scanning Probe Microscope (SPM) Atomic Force Microscopes (AFM) Scanning Tunneling Microscope (STM) Bio-Nanorobotics Magnetically Guided Bacteria-BasedGlobal Nanorobotics Market, By Application

Nanomedicine Biomedical Mechanical OthersGlobal Nanorobotics Market, By Region

North America Europe Asia Pacific Middle East and Africa South AmericaKey players operating in Global Nanorobotics Market:

Bruker JEOL Thermo Fisher Scientific Ginkgo Bioworks Oxford Instruments EV Group Imina Technologies Toronto Nano Instrumentation KlockeNanotechnik KleindiekNanotechnik Xidex Synthace Park Systems Smaract Nanonics ImagingKey Innovators:

Novascan Technologies Angstrom Advanced Hummingbird Scientific NT-MDT Spectrum Instruments Witec

MAJOR TOC OF THE REPORT

Chapter One: Nanorobotics Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanorobotics Market Competition, by Players

Chapter Four: Global Nanorobotics Market Size by Regions

Chapter Five: North America Nanorobotics Revenue by Countries

Chapter Six: Europe Nanorobotics Revenue by Countries

Chapter Seven: Asia-Pacific Nanorobotics Revenue by Countries

Chapter Eight: South America Nanorobotics Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanorobotics by Countries

Chapter Ten: Global Nanorobotics Market Segment by Type

Chapter Eleven: Global Nanorobotics Market Segment by Application

Chapter Twelve: Global Nanorobotics Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanorobotics Market Report at: https://www.maximizemarketresearch.com/market-report/global-nanorobotics-market/30888/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

View post:
Global Nanorobotics Market : Industry Analysis and Forecast (2019-2026) by Type, Application, and Region - MR Invasion

Nanomedicine – Overview – NIH Common Fund

Posted on November 21, 2017 by Prof Baldwin

Background

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. A nanometer is one-billionth of a meter, too small to be seen with a conventional lab microscope. It is at this size scale about 100 nanometers or less that biological molecules and structures operate in living cells.

The NIH vision for Nanomedicine is built upon the strengths of NIH funded researchers in probing and understanding the biological, biochemical and biophysical mechanisms of living tissues. Since the cellular machinery operates at the nanoscale, the primary goal of the program - characterizing the molecular components inside cells at a level of precision that leads to re-engineering intracellular complexes - is a monumental challenge.

The teams selected to carry out this initiative consist of researchers with deep knowledge of biology and physiology, physics, chemistry, math and computation, engineering, and clinical medicine. The choice and design of experimental approaches are directed by the need to solve clinical problems (e.g., treatment of sickle cell disease, blindness, cancer, and Huntingtons disease). These are very challenging problems, and great breakthroughs are needed to achieve the goals within the projected 10 year timeframe. The initiative was selected for the NIH Roadmap (now Common Fund) precisely because of the challenging, high risk goals, and the NIH team is working closely with the funded investigators to use the funds and the intellectual resources of the network of investigators to meet those challenges.

10 Year Program Design High Risk, High Reward

The Centers were funded with the expectation that the first half of the initiative would be more heavily focused on basic science with increased emphasis on application of this knowledge in the second five years. This was a novel, experimental approach to translational medicine that began by funding basic scientists interested in gaining a deep understanding of an intracellular nanoscale system and necessitated collaboration with clinicians from the outset in order to properly position work at the centers so that during the second half of the initiative, studies would be applied directly to medical applications. The program began with eight Nanomedicine Development Centers (NDCs), and four centers remain in the second half of the program.

Clinical Consulting Boards (CCBs)

The program has established Clinical Consulting Boards (CCBs) for each of the continuing centers. These boards consist of at least three disease-specific clinician-scientists who are experts in the target disease(s). The intent is for CCBs to provide advice and insight into the needs and barriers regarding resource and personnel allocations as well as scientific advice as needed to help the centers reach their translational goals. Each CCB reports directly to the NIH project team.

Translational Path

In 2011, the PIs of the NDCs worked with their CCBs to precisely define their translational goals and the translational research path needed to reach those goals by the end of the initiative in 2015. To facilitate this, the NIH project team asked them to develop critical decision points along their path. These critical decision points differ from distinct milestones because they may be adjusted based on successes, challenges, barriers, and progress. Similarly, the timing of these decision points may be revised as the centers progress. Research progress and critical decision points are revisited several times a year by the CCB and the NIH team, and when a decision point is reached, next steps are re-examined for relevance, feasibility and timing.

Transition plan

Throughout the program, various projects have been spun off of work at all the centers and most have received funding from other sources. This was by design as work at each center has been shifting from basic science to translational studies. Centers will not be supported by the common fund after 10 years. It is expected that work at the centers will be more appropriately funded by other sources. Pre-clinical targets will likely be developed, and the work at each center will be focused on a specific disease so the work will need to transition out of the experimental space of the common fund.

Support for the NIH Nanomedicine Initiative is provided by the NIH Common Fund, and a team of staff members from across the NIH oversees the program. You may direct questions or comments on the NIH Nanomedicine Initiative to Dr. Richard S. Fisher, Nanomedicine Project Team Leader (nano@nih.gov).

Excerpt from:
Nanomedicine - Overview - NIH Common Fund

Nanomedicine Conferences | NanoPharma Conferences 2018 …

Posted on November 22, 2017 by Prof Baldwin

Sessions/Tracks

ConferenceSeries Ltdis a renowned organization that organizes highly notableconferencesthroughout the globe. Currently we are bringing forth14thInternational Conference and Exhibition onNanomedicine andPharmaceutical Nanotechnology(NanoMed 2018)scheduled to be held duringApril 16-18, 2018atAmsterdam, Netherlands.The conferenceinvites all the participants across the globe to attend and share their insights and convey recent developments in the field of Pharmaceutical Nanotechnology and Clinical Trials.

The main theme of the conference is Emerging Importance of Nanotechnology to Drive the Pharma Industry.

ConferenceSeries Ltdorganizes aconference seriesof 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientificsocietiesand publishes 700+Open access Journalswhich contains over 50000 eminent personalities, reputed scientists as editorial board members.

14thInternational Conference and Exhibition onNanomedicineandPharmaceutical Nanotechnologyaims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nanotechnology and Nanomedicine. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields ofNanotechnologyand Nanomedicine.

Medicinehas developed throughout time but has remained forever concerned with the maintenance of health and thus the science of prevention and alleviation, and ultimately curing, of disease. To continue its development in new directions, medicine is now looking to nanomedicine, an emerging scientific specialty born from nanotechnology, which has grown up in the fields ofengineering, physics,chemistryandbiotechnology, and is now moving into medicine, with huge potential for expansion and development over the next decade and beyond.

As our knowledge of the human body continues to improve, nanotechnology will be developed to monitor, repair and control human biological systems at the molecular level. This conference will offer unique opportunities for developing new therapeutic approaches to diagnose, prevent, treat and eradicate life-threatening diseases and conditions (such as cancer and diabetes), as well as resolving pain and improving medical techniques (such as bone repair and surgical techniques), through various novel nanotechnological approaches.

Nanomedicineis a uniquely addressing the important challenges and advances in medicalnanoscale-structured materialand devices,biotechnology devicesand molecular machine systems andnanorobotics. NanoMed 2018 is a valuable information source for all players in the field academic, industrial and clinical researchers, pharmaceutical and biotechnology companies,regulatory authoritiesand others across the scientific community.

Track 1:NanomedicineandBiomedical Applications:

Nanomedicineis simply the application of nanotechnologies in a healthcare setting and the majority of benefits that have already been seen involve the use ofnanoparticlesto improve the behaviour ofdrug substances. Today, nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian andbreast cancer, kidney disease, fungal infections,elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain,asthmaand emphysema. The nanomedicines that are currently available are overcoming some of the difficulties experienced by normal medical approaches in delivering the benefit from thedrug moleculesused. In some cases the drugs have very little solubility in water and the human body struggles to absorb enough to treat the condition. In other cases, the drug molecule is absorbed well but the body removes the drug before it has had long enough to provide a benefit. Drugs may lead to side-effects due to poor delivery at the actual site of disease. For example, drugs that are targeting cancers must avoid healthy tissues and organs or damage can be caused. Nanomedicines therefore can play an important role in ensuring enough of the drug enters the body, that drug that does enter stays in the body for long periods and is targeted specifically to the areas that need treatment.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society - Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 2:Design of Nanodrugs

To date, variousnanodrug systemshave been developed for different routes of administration, which include dendrimers,nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. Nanodrug systems have been employed to improve the efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profile of pharmaceutical substances. In particular, functionalized nanodrug systems can offer enhancedbioavailabilityof orally taken drugs, prolonged half-life of injected drugs (by reducing immunogenicity), andtargeted delivery to specific tissues. Thus,nanodrug systemsmight lower the frequency of administration while providing maximized pharmacological effects and minimized systemic side effects, possibly leading to better therapeutic compliance and clinical outcomes. In spite of these attractive pharmacokinetic advantages, recent attention has been drawn to the toxic potential of nanodrugs since they often exhibit in vitro and in vivo cytotoxicity, oxidative stress, inflammation, and genotoxicity

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 3:Design & Characterization of Nanosystems

Micro andNanosystemspublishes significant original work, topical reviews and guest edited issues ranging from technologies and systems to product innovation and new manufacturing processes with features at the micro and nanoscale. Applications for micro and nanosystems in areas such as health, environment, food, security and consumer goods are covered. The topics to be addressed include Lab-on-a-chip,microfluidics, nano-biotechnology, micro andnanomanufacturing, printed electronics and MEMS.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 4:NanomedicineandNanotechnology

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use ofnanoscale materials, such as biocompatible nanoparticles andnanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism.Nanotechnologyhas many definitions but in general it is the use and application of materials with sizes in the nanometre range. Just as a millimetre is one-thousandth of a metre, a nanometre is one-millionth of a millimetre. In more understandable terms, a human hair is approximately 80,000 nanometres in diameter and the growing science and industry of nanotechnology utilises materials below 1000 nanometres. Benefits of working at this very small scale have been seen for many years over such diverse areas as electronics and energy storage to sunscreens and food packaging.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 5:Pharmaceutical Nanotechnology

Pharmaceutical Nanotechnologydeals with emerging new technologies for developing customized solutions fordrug delivery systems. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. In addition to this the drug delivery system also allows the drug to bind to its target receptor and influence that receptors signaling and activity. Pharmaceutical nanotechnology embraces applications of nanoscience to pharmacy asnanomaterials, and as devices likedrug delivery, diagnostic, imaging and biosensor.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 6:Synthesis of NanoparticlesforDrug Delivery

Synthesizingnanoparticlesfor pharmaceutical purposes such as drug preparation can be done in two methods. Bottom up process such as pyrolysis, inert gas condensation, solvothermal reaction, sol-gel fabrication and structured media in which hydrophobic compound such asliposomesare used as bases to mount the drug. Top down process such as attrition / milling in which the drug is chiseled down to form a nanoparticle.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 7:Regenerative MedicineandTissue Engineering

Tissue engineeringis a branch of regenerative medicine, itself a branch ofbiomedical engineering. Tissue engineering andregenerative medicineare concerned with the replacement or regeneration of cells, tissues (the focus of tissue engineers) or organs to restore normal biological function.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 8:Drug Delivery Research

Drug deliveryis an essential part ofpharmaceutical sciencesthat should be taken into account early in thedrug discoveryand development process. A drug that cannot be delivered to its site of action is essentially useless. Drug delivery is affected by the physico-chemical properties of the drug and formulation and the interplay of these factors with the transport, binding, and metabolism of the drug in the body. New tools are needed to accurately predict delivery properties of the compounds early during drug discovery, so that the best compounds can be identified for clinical studies. Another class of tools includes the delivery methods that facilitate delivery of hard-to-deliver compounds to the appropriate target sites. Delivery of gene-based drugs (DNA, oligonucleotides, siRNA) and proteins is a major challenge in pharmaceutical science. Nanotechnology can be used to improve drug delivery in these difficult cases. The development and use of nanoparticles in theformulationof these types of drugs is a major focus at CDR, and we welcome productive industrial partnerships to develop these tools for translational use.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 9:Novel Drug Delivery Systems

Novel Drug delivery systemis the advancedrug delivery systemwhich improvedrug potency,control drug releaseto give a sustained therapeutic effect, provide greater safety, finally it is to target a drug specifically to a desired tissue.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 10:Smart Drug Delivery Technology

With the unprecedented progresses ofbiomedical nanotechnologyduring the past few decades, conventionaldrug delivery systems(DDSs) have been involved into smart DDSs with stimuli-responsive characteristics. Benefiting from the response to specific internal or external triggers, those well-defined nanoplatforms can increase the drug targeting efficacy, in the meantime; reduce side effects/toxicities of payloads, which are key factors for improving patient compliance. In academic field, variety of smart DDSs have been abundantly demonstrated for various intriguing systems, such as stimuli-responsivepolymeric nanoparticles, liposomes, metals/metal oxides, and exosomes.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 11:Nano Pharmaceuticals

Nanopharmaceuticalsoffer the ability to detect diseases at much earlier stages and the diagnostic applications could build upon conventional procedures using nanoparticles. Nanopharmaceuticals represent an emerging field where the sizes of thedrug particleor a therapeutic delivery system work at thenanoscale. In the pharmaceutical industry, a long standing issue is the difficulty of delivering the appropriate dose of a particular active agent to specific disease site. Nanopharmaceuticals have enormous potential in addressing this failure of traditional therapeutics which offers site-specific targeting of active agents. Such precision targeting via nanopharmaceuticals reduces toxic systemic side effects, resulting in better patient compliance. In todays world economy, apharmaceutical industryfaces enormous pressure to deliver high-quality products to patients while maintaining profitability. Thereforepharmaceutical companiesare applying nanotechnology to enhance or supplement drug target discovery anddrug delivery. Nanopharmaceutical reduces the cost of drug discovery, design & development and enhances the drug delivery process. This results in the improvedResearch & Developmentsuccess rate which enables faster introduction of new, cost-effective products to the marketplace.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

Related Societies:

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 12:Nanobiotechnology

Nanobiotechnology,bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology andbiology. This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts that are enhanced throughnanobiologyinclude:nanodevices(such asbiological machines), nanoparticles, and nanoscale phenomena that occurs within the discipline of nanotechnology. This technical approach to biology allows scientists to imagine and create systems that can be used forbiological research. Biologically inspired nanotechnology uses biological systems as the inspirations for technologies not yet created.

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 - 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 - 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 - 14, 2018 at Venice,Italy.

See the original post here:
Nanomedicine Conferences | NanoPharma Conferences 2018 ...

Wiley Interdisciplinary Reviews: Nanomedicine and …

Posted on July 6, 2015 by Prof Baldwin

Impact Factor: 4.239 Read, cite the journal, or submit your paper to keep contributing to the success of WIREs Nanomedicine and Nanobiotechnology

NanoMedicine-2013 is a dedicated event for the nanotech community and aims to offer professionals in the field a multidisciplinary platform to learn more about the latest scientific updates and industrial standards. Nanomedicine-2013 will consist of six tracks covering current advances in many aspects of nano-medicine R & D and business. The conference will consist of keynote forum, panel discussions, free communication, poster presentations and an exhibition. Through these dynamic scientific and social events, you will have many opportunities to network and to form potential business collaborations with participants from all over the world.

From 2012 (Volume 4), access to the full content of WIREs Nanomedicine and Nanobiotechnology is through a subscription only. Subscribe here or use our easy online library recommendation form to recommend this title to your librarian today.

If your institution opted-in last year, you will retain access to content back to 2009, including all of our special collections.

Never miss an issue! Get the table of contents emailed to your inbox for free each time an issue is published online. Under Journal Tools:

And don't forget to follow us on

More here:
Wiley Interdisciplinary Reviews: Nanomedicine and ...

Nanomedicine Research Journal

Posted on September 3, 2017 by Prof Baldwin

Nanomedicine Research Journal (Abbreviation: Nanomed Res J)

is an international, open access, peer-reviewed, electronic and print quarterly publication released by the Iranian Society of Nanomedicine (ISNM). Nanomedicine Research Journal publishes original research articles, review papers, mini review papers, case reports and short communications covering a wide range of field-specific and interdisciplinary theoretical and experimental results related to applications of nanoscience and nanotechnology in medicine including, but not limited to, diagnosis, treatment, monitoring, prediction and prevention of diseases, tissue engineering, nano bio-sensors, functionalized carriers and targeted drug delivery systems.

* Publication process of manuscripts submitted to Nanomed Res J is free of charge.

To see Acceptance timeline Please follow the link below:

Acceptance Timeline Diagram

About the publisher

Founded in 2011 by the leading ofSchool of Advanced Technologies in medicine (SATiM),Tehran University of Medical Sciences (TUMS) and Iran Nanotechnology Initiative Council, the Iranian Society of Nanomedicine (ISNM) attempts to promote and develop medical nanotechnology in Iran. For more information about the publisher, please visit us at http://isnm.ir/en/.

Here is the original post:
Nanomedicine Research Journal

Nanomedicines can save thousands. Indiegogo – Global Nanomedicine – Video

Posted on September 4, 2014 by Prof Baldwin

Nanomedicines can save thousands. Indiegogo - Global Nanomedicine
Indiegogo Crowd-funding Global NanoMedicine. Website: http://igg.me/at/Savenanos.

By: Miguel Vidal

The rest is here:
Nanomedicines can save thousands. Indiegogo - Global Nanomedicine - Video

013 Ninjas vs Superbugs Adventures in Nanomedicine – Video

Posted on September 11, 2014 by Prof Baldwin

013 Ninjas vs Superbugs Adventures in Nanomedicine

By: Sophia Wight

Impact of Existing and Emerging Europe Nanomedicine Market – MilTech

Posted on August 28, 2017 by Prof Baldwin

The global Nanomedicine Market size was estimated at USD XX billion in 2017. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2022.

Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2022.

Ability of the nanotechnology to serve in diagnostics as well as the therapeutic sector at the same time as a consequence of its characteristic principle to is anticipated to augment research in this sector. Furthermore, utilization of DNA origami for healthcare applications is attributive for the projected growth.

The global nanomedicine market is segmented based on modality, application, indication, and region. Based on application, it is classified into drug delivery, diagnostic imaging, vaccines, regenerative medicine, implants, and others.

On the basis of indication, it is categorized into oncological diseases, neurological diseases, urological diseases, infectious diseases, ophthalmological diseases, orthopedic disorders, immunological diseases, cardiovascular diseases, and others. Based on modality, it is bifurcated into treatments and diagnostics.

The global market is driven by emerging technologies for drug delivery, increase in adoption of nanomedicine across varied applications, rise in government support & funding, growth in need for therapies with fewer side effects, and cost-effectiveness of therapies. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth.

Download Sample Pages @http://www.kminsights.com/request-sample-33081

Contact:

Mr.Mannansales@kminsights.com+1 (888) 278-7681

About Us:Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Read the original post:
Impact of Existing and Emerging Europe Nanomedicine Market - MilTech

Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan) – Video

Posted on August 23, 2014 by Prof Baldwin

Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan)
Prof. Pan joined University of Illinois in fall 2013. Previously, He was an Assistant Professor of Medicine, Research at the Division of Cardiology, Washington University in St. Louis. He also...

By: NanoBio Node

Read the original post:
Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan) - Video

Global Business Jets Market To Be Driven By The Rising Number Of Staff And The Introduction Of Fresh Aircraft Programs In The Forecast Period Of…

Posted on March 25, 2022 by Prof Baldwin

The new report by Expert Market Research titled, GlobalBusiness Jets MarketReport and Forecast 2021-2026, gives an in-depth analysis of the global business jets market, assessing the market based on its segments like aircraft type, end use, systems, services, platform and major regions like North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report [emailprotected]https://www.expertmarketresearch.com/reports/business-jets-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The market for business jets has seen substantial growth due to factors such as the increasing number of staff and the introduction of fresh aircraft programs. Also, increased knowledge across different segments offers an enormous market opportunity for key players in the business jets market. The light aircraft segment is expected to grow at the fastest rate during the forecast period. The expansion of the light aircraft segment can be attributed to its growing use as business jets for inter- and intra-city transportation, as well as greater brand marketing by manufacturers. The sector is expected to grow even more as technology advances and the middle-class population grows. The business jet industry is expected to grow as air mobility improves in both developed and developing countries.

Industry Definition and Major Segments

A private jet, often known as a business jet or bizjet, is a jet aircraft designed to transport small groups of people. Business jets can be customised for specific missions, such as casualty evacuation or parcel delivery, and some are used by public bodies, government officials, and the military services.

Explore the full report with the table of [emailprotected]https://www.expertmarketresearch.com/reports/business-jets-market

Based on the aircraft type, the industry is divided into:

Based on the end use, the industry is divided into:

Based on the system, the industry is divided into:

Based on the services, the industry is divided into:

Based on the platform, the industry is divided into:

The regional markets for business jets include:

Market Trends

Geographically, North America currently holds the largest market share and is likely to maintain that position throughout the forecast period. The region has the worlds largest operational business jet fleet, with the United States accounting for most of them. Most of the demand is for light and large jets due to the presence of numerous high-net-worth people and corporate companies. In addition, there has been a rise in demand for charter services in the region during the last few years. In 2020, demand for business aviation has increased as a result of COVID-19s influence on commercial aviation. Even though overall flight activity decreased in 2020, business aviation flight activity began to recover steadily in May of that year. Furthermore, following the lifting of COVID-19 pandemic restrictions in the region in 2021, corporate jet activity began to surge. In addition, charter companies have reduced their pricing to accommodate the business jet prospects. The expansion of charter operations in the region has prompted charter operators to embark on fleet modernization plans in order to improve fleet efficiency.

Key Market Players

The major players in the market are APG-Neuros, Safran S.A. (SAF (EPA)), Curtiss-Wright Corporation (CW (NYSE)), Esterline Technologies Corporation, Meggitt PLC (MGGT (LON)), United Technologies Corporation (UTX (NYSE)), Eaton Corporation Inc (ETN (NYSE)), Ametek, Inc. (AME (NYSE)), among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

How to introduce Nanomedicine Products and bring their Impact to the Market? – Video

Posted on March 6, 2015 by Prof Baldwin

How to introduce Nanomedicine Products and bring their Impact to the Market?
Speaker: Dr. Christopher R. Anzalone, Ph.D., President and CEO, Arrowhead Research Corporation Pasadena, CA (USA) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

Go here to see the original:
How to introduce Nanomedicine Products and bring their Impact to the Market? - Video

Panel – Nanomedicine and Targeted Drug Delivery – Video

Posted on March 6, 2015 by Prof Baldwin

Panel - Nanomedicine and Targeted Drug Delivery
CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

See the article here:
Panel - Nanomedicine and Targeted Drug Delivery - Video

Significant EU funding awarded to nanomedicine research Blue light used to release pharmaceutical agents at the target – India Education Diary

Posted on December 13, 2020 by Prof Baldwin

ProfessorTimo Laaksonen, who divides his time between the University of Helsinki and Tampere University, has received a grant of roughly 2 million from the European Research Council (ERC). Laaksonens research focuses on releasing pharmaceutical agents in a controlled way in the body using blue or ultraviolet light.

Employing light in drug release is not a new invention as such. With the help of red light, for instance, the membrane of a liposome transporting a nano-sized drug can be made more permeable, releasing the drug. However, blue light provides a more extensive set of tools compared to red light.

Blue and UV light have more energy, powerful enough, for example, to break up chemical bonds in a certain type of drug carrier and detach the drug molecules bound to the carriers surface, Laaksonen explains.

Earlier, the use of UV light has been hindered by the fact that, even at its best, it travels less than a hundred micrometres in the tissue, or the breadth of a single average hair. Red light advances much further. That UV light can damage the body adds another complication, while red light is markedly safer.

Laaksonen is now focusing on how to safely target blue or UV light to the site where the drug should be released. There are two options: either photons could be locally upconverted to a higher energy level inside the body, or a variety of drug implants activated by light could be used.

In practice, photoactivation could potentially be used to release drugs, for example, at the precise moment when another dose is needed. It could be a certain time every morning, or we could continually adjust the release rate to suit the patient.

Timo Laaksonen heads research groups at both the Faculty of Pharmacy, University of Helsinki and the Faculty of Engineering and Natural Sciences, Tampere University. The pharmacy component of the project is carried out in Helsinki and the photochemical component in Tampere. The University of Helsinki will receive 60% of the ERC grant and Tampere University 40%.

Go here to see the original:
Significant EU funding awarded to nanomedicine research Blue light used to release pharmaceutical agents at the target - India Education Diary

SpaceX Takes Remotely Controlled Drug Delivery System to the ISS – Interesting Engineering

Posted on September 3, 2021 by Prof Baldwin

The International Space Station (ISS) is a unique laboratory available to mankind. The micro-environment, the extreme conditions, and the demanding requirements of space make it an excellent test field for new ideas and devices. Reaching the ISS laboratory this Monday is a next-generation implantable drug delivery system that can be operated remotely and could be used to treat and even prevent chronic ailments back on Earth.

The system is one of the many science experiments that were launched on theCommercial Resupply Services 23 (CRS-23), undertaken by SpaceX and NASA. The third mission for SpaceX, under an agreement, where privately operated spacecraft transport cargo and supplies to the ISS, used the Cargo Dragon 2 capsule, and reused a Falcon 9 booster, NASA said in a press release.

Considered insignificant and irrelevant to human existence just a couple of decades ago, experiments on the ISS are now looked at as a gateway to the science of the future. As colonization of planets comes closer to reality, it is pertinent to know the impact of space travel on humans and also if materials known on Earth retain their properties in different environments. More than 3,000 experiments have been carried out onboard the ISS so far, Nature reportedlast year.

Joining the list is the remotely controlled implantable drug delivery system, developed by Professor of Nanomedicine,Alessandro Grattoni, and his team at the Houston Methodist Research Institute. The purpose of the implantable drug delivery systems is to deliver precise quantities of medication only to target delivery sites in the body. While previous iterations have used specialized membranes to do this passively, Grattoni and his team have now developed an active system that can be controlled remotely using an app.

Faraday Research Facility (FRF), a multi-purpose research facility that is designed to connect with the ISS, houses the system. Inside the FRF are smaller chambers that can hold different experiments in place to be conducted in space. Developed byProXopS, LLC, the FRF can hold up to 12 research environments in place and can be operated from the ground using the ISS Wi-Fi.

Grattoni's trial system consists of sealed containers of saline tubes that will be operated from the ground. If successful, a future flight will use this system to deliver drug doses in rodent subjects, enabling complex drug dose regimens without stressing the subjects, the press release said. Apart from using the system for telemedicine back on Earth, it might also be utilized in astronauts who are on long-duration space missions and for diseases such ashypertension, rheumatoid arthritis, and sleep disorders.

Also on board the FRF is an experiment from the Girl Scouts who have sent ants to see how they colonize in low-gravity environments.

Onboard the cargo that will dock on Monday is a robotic arm from GITAI Japan to the feasibility of using robots to do routine and hazardous tasks in orbit. The technology could also be applied for disaster relief and servicing of nuclear power plants, back on Earth, said a NASA press release.

Astronauts on the ISS will also use a device that will attach to their iPad and take images of their retina. This is expected to improve our understanding ofSpace-Associated Neuro-Ocular Syndrome (SANS), seen in two-third of the astronauts, who have spent a month or longer in space.

Go here to see the original:
SpaceX Takes Remotely Controlled Drug Delivery System to the ISS - Interesting Engineering

Nanotechnology in Medical Applications Market Investigation Highlights Growth Trends in COVID-19 the Coming Years – The Daily Philadelphian

Posted on November 10, 2020 by Prof Baldwin

The global nanomedical market was valued at $134.4 billion in 2016. This market is projected to grow at a compound annual growth rate (CAGR) of 14.0% from 2017-2022, and should reach $293.1 billion by 2022 from $151.9 billion in 2017.

Report Scope:

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

Click Here to Get Sample Premium Report @ https://www.trendsmarketresearch.com/report/sample/12261

Report Includes:

An overview of the global markets for nanotechnology used in medical applications Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022 A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market

Summary

Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.

The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.

Reasons for Doing the Study

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/12261

Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) – The Media Line

Posted on December 4, 2020 by Prof Baldwin

Tel Aviv University researchers use tiny molecular scissors to target aggressive metastatic cancer cells

Israeli scientists have developed a cutting-edge nanotechnology system that can destroy cancerous cells in mice.

The Tel Aviv University team of researchers pioneered a treatment method that is so precise, it is almost as if tiny molecular scissors were being used to kill the cancer.

We developed a delivery system for these molecular scissors that can specifically reach tumor cells while leaving normal cells intact, Dr. Daniel Rosenblum, a postdoctoral fellow from the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University, told The Media Line.

By cutting their DNA in specific genes that are responsible for cell division or cell survival, we basically neutralize them and they die from the treatment, he said. The system we developed is based on the Cas9 CRISPR protein in a [messenger] RNA format.

The process, known as CRISPR genome editing, allows researchers to alter DNA sequences. Specifically, scientists at the university created what is known as CRISPR-LNPs, a lipid nanoparticle delivery system that carries a genetic messenger (known as messenger RNA), along with a navigation system that can recognize cancerous cells.

The findings of the peer-reviewed research were published last month in the Science Advances journal.

This is the first study in the world to prove that the CRISPR genome editing system can be used to treat cancer in a living animal effectively,said Prof. Dan Peer, vice president for Research and Development at Tel Aviv University and head of TAUs Laboratory of Precision NanoMedicine.

The idea there is to take the cells from the patients, edit them in a plate outside the body and then inject them back into the patient, he told The Media Line. We believe that this could be expanded to much more than just the two models that we have tried.

So far, researchers at Tel Aviv University have tested the technology on mice and have observed no adverse reactions. This stands in contrast to chemotherapy, which kills both cancerous and healthy cells.

The CRISPR-LNPs were tested on glioblastoma tumors, an extremely aggressive type of brain cancer that has a five-year survival rate of only 3%. In addition, the researchers tested the system on metastatic ovarian cancer, a major cause of death among women and the most lethal cancer in the female reproductive system.

Wake up to the Trusted Mideast News source Mideast Daily News Email

For the glioblastoma tumors, the treatment was found to double the average life expectancy of mice and improve their overall survival rate by about 30%. For ovarian cancer, the overall survival rate rose by a whopping 80%.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried

We envision that we can simply inject [the treatment] into the body and because of the GPS they can find their way to the tumor, Anna Gutkin, a doctoral student in the laboratory, told The Media Line. We encountered several hurdles in the development of this technology but its exciting to work on this. It really opens new avenues for us to develop novel therapies.

Aside from its potentially revolutionary impact on future cancer treatments, the technology also opens the door for treating rare genetic diseases and viral diseases such as AIDS, according to the researchers. A similar technology based on messenger RNA currently is being used by Pfizer (BioNTech) and Moderna for their COVID-19 vaccines.

Our system is a bit more sophisticated both from the materials they are created from [and] we also gave it a GPS system, which is pretty unique, Rosenblum noted.

In the future, Peer and his team hope to test the groundbreaking technology on larger animal models. Human trials are expected to begin in about two years.

Because of the coronavirus crisis we have witnessed how fast new approaches could be translated into the clinic, Peer said.

When we started we thought this was a science-fiction approach but basically it works, at least in the animal models that we have tried, he concluded.

The rest is here:
Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) - The Media Line

Futurist Transhuman News Blog

Category Archives: Nanomedicine

Nanomedicine Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept – BioSpace

Impact of COVID-19 on Nanomedicine Market Top Companies Analysis To growing at CAGR of 12.6% by 2023 – Cole of Duty

International Journal of Nanomedicine | Volume 13 – Dove Press

Global Nanorobotics Market : Industry Analysis and Forecast (2019-2026) by Type, Application, and Region – MR Invasion

Nanomedicine – Overview – NIH Common Fund

Nanomedicine Conferences | NanoPharma Conferences 2018 …

Wiley Interdisciplinary Reviews: Nanomedicine and …

Nanomedicine Research Journal

Nanomedicines can save thousands. Indiegogo – Global Nanomedicine – Video

013 Ninjas vs Superbugs Adventures in Nanomedicine – Video

Impact of Existing and Emerging Europe Nanomedicine Market – MilTech

Translational Nanomedicine in the Interface of Chemistry, Biology, and Engineering (Dipanjan Pan) – Video

Global Business Jets Market To Be Driven By The Rising Number Of Staff And The Introduction Of Fresh Aircraft Programs In The Forecast Period Of…

How to introduce Nanomedicine Products and bring their Impact to the Market? – Video

Panel – Nanomedicine and Targeted Drug Delivery – Video

Significant EU funding awarded to nanomedicine research Blue light used to release pharmaceutical agents at the target – India Education Diary

SpaceX Takes Remotely Controlled Drug Delivery System to the ISS – Interesting Engineering

Nanotechnology in Medical Applications Market Investigation Highlights Growth Trends in COVID-19 the Coming Years – The Daily Philadelphian

Israeli Scientists Kill Cancer With Revolutionary DNA-Altering Treatment (with VIDEO) – The Media Line